Ipsen's Phase II FALKON Trial for Ultra-Rare Bone Disease FOP Fails to Meet Primary Endpoint
Key Insights
Ipsen announced that its pivotal Phase II FALKON trial failed to meet the primary endpoint of reducing new heterotopic ossification (search) in patients with fibrodysplasia ossificans progressiva (search) (FOP (search)), leading to study closure.
The trial enrolled 113 patients globally over five years to evaluate fidrisertib, an oral ALK2 (search) kinase inhibitor designed to target the underlying cause of FOP (search).
Despite the disappointing results, fidrisertib was generally well tolerated with no safety concerns, and the data will contribute to the growing body of FOP (search) research.
Ipsen announced on December 19, 2025, that its pivotal Phase II FALKON trial did not meet its primary endpoint of reducing new heterotopic ossification (search) (HO) in adults and children living with fibrodysplasia ossificans progressiva (search) (FOP (search)) compared to placebo, resulting in the study's closure. The investigational drug fidrisertib was generally well tolerated, with no safety concerns identified during the trial.
"These results are disappointing for the FOP (search) community and patients living with this devastating disease," said Christelle Huguet, PhD, EVP, Head of Research and Development at Ipsen. "However, we do believe that these data will contribute to the growing body of research on FOP, giving new insights into managing this disease for patients and their care providers."
Trial Design and Scope
FALKON represents the largest Phase II trial conducted in FOP (search), comprising three parts designed to evaluate the efficacy, safety and tolerability of fidrisertib as a first-line treatment in pediatric and adult patients. The trial enrolled 113 patients globally, taking over five years to reach this critical milestone.
Part A consisted of a global, multi-center, placebo-controlled, parallel-group, 3-arm trial. Patients aged 5 years or older with the R206H ACVR1 (search) mutation or other FOP (search) variants associated with progressive HO were randomized to receive either high dose-weight based or low dose weight-based fidrisertib or placebo. The primary endpoint was annualized change from baseline in HO volume.
In Part B of the double-blind trial, patients continued their dose of fidrisertib, with placebo patients from Part A also randomized to receive either high or low dose fidrisertib. Part C was designed as an extension period for all responding patients.
Understanding FOP and Its Impact
FOP (search) is a genetic condition caused by pathogenic variants of the ALK2 (search) kinase that leads to bone formation in soft and connective tissues, including muscles, tendons and ligaments, through a process known as heterotopic ossification (search). Once formed, HO is irreversible, and there are limited treatment options available for patients with FOP.
The disease has devastating consequences for patients and families. The average age of diagnosis is 5 years old, and FOP (search) ultimately shortens life expectancy to a median of 56 years. Untimely death is typically caused by bone formation around the ribcage, leading to breathing problems and thoracic insufficiency.
FOP (search) has an estimated prevalence of 1.36 per million individuals, with approximately 900 people diagnosed worldwide, though the number of confirmed cases varies by country.
Fidrisertib Mechanism and Administration
Fidrisertib is an oral, highly selective and potent small molecule inhibitor of pathogenic variants of the ALK2 (search) kinase, targeting the underlying root cause of FOP (search). The drug has been designed to address both the unliganded ALK2 signal and BMP and aberrant activin liganded signals during flare-ups, impacting both flare-up based and non-flare-up based HO formation.
The medication is administered orally as a capsule that can be sprinkled on food or dissolved in water, with no dose changes required during flare-ups.
Company Commitment Despite Setback
Despite the trial's failure to meet its primary endpoint, Ipsen emphasized its continued commitment to the FOP (search) community. Huguet acknowledged the tremendous undertaking that FALKON represented and thanked the patients, caregivers, FOP community and key opinion leaders who dedicated their time to the trial.
The company noted that while the results were disappointing, the data generated will contribute valuable insights to the scientific understanding of FOP (search) and may inform future research efforts in managing this devastating rare disease.